Newer Omicron Types Initiate Their Own Coronavirus Waves
The data is undeniable: COVID-19 instances and hospitalizations are on the rise in the United States, despite patchy documentation. Most states are witnessing an upsurge,...
Pfizer Binds With $22B Paxlovid Plan Amidst Slow Demand
Pfizer officials stated on an earnings call that while Paxlovid's first-quarter sales may seem to be low, there will be plenty more revenues in the...
Teva And Lupin Reach Settlement In AUSTEDO Patent Dispute
Austedo, Teva's tardive dyskinesia (TD) therapy, has great prospects. Now the company only needs to worry about one less generic pharmaceutical presenting a threat...
CDC Suggests Majority of Americans Have COVID-19 Antibodies
According to updated information from the US Centers for Disease Control and Prevention, about 60% of adults plus 75% of children have antibodies suggesting...
Camzyos, Possible Mega Cardiac Drug Given Green Light By FDA
Bristol Myers Squibb has gained approval for one of the year's most anticipated medications, following a brief delay in November. Camzyos, a drug developed...
Dupixent From Sanofi Delivers Another Fantastic Performance
Sanofi's Dupixent is still breaking new ground in inflammatory illnesses five years after receiving FDA approval for the first time in eczema. Bill Sibold,...
Rinvoq From Abbvie Gets Fourth FDA Approval In Five Months
The pharma version of Fast and Furious has a new superhero. How else to characterise AbbVie's Rinvoq's breakthrough effectiveness? The immunology medicine received its...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...